Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chinese patent medicines versus aspirin for stable angina in coronary heart disease
ChiCTR2200064893Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
- Start
- Oct 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of qishen yiqi dripping pills, Shexiang Baoxin Pill, danlou and aspirin in coronary arteriosclerosis and stable angina (4 arms), sponsored by Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine. Primary endpoint: Seattle Angina Questionnaire score. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
qishen yiqi dripping pillsShexiang Baoxin Pilldanlouaspirin
03
Conditions
coronary arteriosclerosisstable angina
Beyond the preview
Go deeper on ChiCTR2200064893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064893.